Nicole Bentivegna, PharmD, BCOP

Amivantamab with lazertinib emerges as a promising frontline therapy for EGFR-mutated metastatic NSCLC, enhancing overall survival and treatment tolerability.

The high acceptance rates of these interventions demonstrate the key role in optimizing patient care that clinical oncology pharmacists with access to medical records play.

The drug solidifies its place as a first-line treatment option in AML.

The program develops patient-centered oncology pharmacists through comprehensive training.

Advancements include novel combination therapies and improved diagnostic techniques.

An overview of current FDA-approved ROS1-targeted therapies.

Multiple P13K inhibitors have showed promise in treating genetically-mutated forms of breast cancer.